For SARS-CoV-2 infection, clinical frailty scale (CFS) scores is an important point of care prognostic indicator of mortality, in which CFS 6–9 can be regarded at elevated risk, CFS 4–5 at moderate risk, and CFS 1–3 people can be regarded at lower risk of mortality irrespective of age.

A systematic review and meta-analysis were carried out for quantifying the effect of CFS by raising the severity of frailty and for identifying other personal prognostic factors linked with raised mortality from coronavirus infection.

Databases such as Web of Science, EMBASE, PsychInfo, MEDLINE, and CAB Abstracts were explored. The relevant publications detected via MedRevix were followed up in peer-reviewed database search, and the citations were upgraded as published.

Retrospective and prospective cohort studies that reported the link between CFS and COVID-19 death were incorporated. Notably, 34 studies were eligible for systematic review while 17 were eligible for meta-analysis, with 81–87% (I2) heterogeneity.

All the 34 studies incorporated people from a hospital setting, consisting of 18,042 patients with a mean age of 72.8 years. The CFS 4–5 participant group had considerably more mortality in comparison with participants with CFS 1–3. Additionally, CFS 6–9 participant group exhibited an even more evident mortality rise in comparison with participants with CFS 1–3.

The generic inverse variance assessment of adjusted hazard ratio among incorporated studies emphasized that CFS, male gender, National Early Warning Score, chronic kidney disease, ischemic heart disease, and hypertension were linked with increased SARS-CoV-2 mortality.